CompletedPhase 1NCT01233440

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Studying Hemophilia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSL Behring
Principal Investigator
Iris Jacobs, MD
CSL Behring
Intervention
Recombinant Coagulation Factor IX Albumin Fusion Protein(biological)
Enrollment
25 enrolled
Eligibility
12-65 years · MALE
Timeline
2010 – 2011

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01233440 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials